Navigation Links
AspenBio Pharma Changes Company Name to Venaxis, Inc.
Date:12/12/2012

dicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize val
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AspenBio Pharma Engages Tiberend Strategic Advisors as Investor and Public Relations Agency of Record
2. AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets
3. AspenBio Pharma to Provide Shareholders with Business Update
4. AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial
5. AspenBio Pharma Announces Proposed Public Offering
6. AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
7. AspenBio Pharma Announces Closing of Public Offering of 1,946,000 Shares of Common Stock
8. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
9. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
10. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
11. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ... sciences company focused on developing stem cell based therapies ... Weinreb , its President and CEO, will be ... The conference will be held on Thursday, May 30, ... E 42nd Street in New York City.  Mr. Weinreb,s ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3STAAR Surgical To Present At Upcoming Investor Conferences 2
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
... WHITE PLAINS, N.Y., Sept. 18 Millennium ... an interim analysis of a large,randomized, international ... in combination with Velcade(R) (bortezomib) showed that ... better. These patients, who are not,eligible for ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients 2
(Date:5/21/2013)... May 21, 2013 The Special Olympics Missouri ... coaches from across the state to Columbia. This state-level event ... University of Missouri and Columbia College, and at Hickman High ... Summer Games officially kick off at 7:30 p.m. Friday, May ... a Go Wild! theme, the Parade of Athletes, the culmination ...
(Date:5/21/2013)... Puroast® Low Acid Coffee has named ... Chairman of the Board. , Among the ... Johnson during his more than 30-year career was as ... Worldwide Chairman of Consumer Pharmaceuticals & Nutritionals and President ... develop and build the market for such brands as ...
(Date:5/21/2013)... VA, May 21, 2013The Journal of the ... today released its June issue, which includes a ... Pediatric Drug-Resistant Tuberculosis. It establishes standardized definitions, ... research. This is the first step as ... visibility and share evidence and resources that can ...
(Date:5/21/2013)... May 21, 2013 Children with autism showed significant ... home using everyday items such as scents, spoons and ... that a treatment known as environmental enrichment led to ... 3 and 12. Results appear online in Behavioral ... Leon randomly assigned 28 boys to one of two ...
(Date:5/21/2013)... meeting of ESHRE (European Society of Human Reproduction & ... medicine. Well over 9000 experts are expected this year, ... much of which is of great public interest. Reports ... good source of news and features. , This year,s ... in London from 7th to 10th July. , The ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Former Johnson & Johnson Executive Brian Perkins Named Chairman of Puroast® Coffee 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2
... Body By Milk MVP, HOUSTON, Oct. 22 ... superstar athletes at Hightower High School. The,National Milk Mustache ... team has earned the title of Body By Milk ... part of the,first-ever nationwide Refuel Your School contest which ...
... Inc. is preparing for its next clinical trial of Cytolin, the breakthrough ... the virus. The preparations come at a time when CytoDyn, Inc. is ... expanded business activities. , ... (PRWEB) October 22, 2008 -- Although HIV ...
... with Super Antioxidant provides ... stress, ORLANDO, Fla., Oct. 21 ... India) are jointly introducing a,new organic dietary ... organic spirulina and astaxanthin in a single ...
... a method of assessing the quality of phase ... oncology conferences: EORTC-NCI-AACR (ENA) [1] and American Society ... Thursday (23 October) at the 20th ENA Symposium ... show there is room for improvement and the ...
... Capitol Hill Briefing, WASHINGTON, Oct. 21 ... and lured into prostitution as a result of ... girls are especially,vulnerable -- runaways, survivors of childhood ... developmental disability, or abuse,drugs/alcohol. They are crime victims, ...
... new moms participate, task force says , , TUESDAY, ... and health systems should encourage and promote breast-feeding, ... Services Task Force. , Members of the task ... interventions conducted in the United States and other ...
Cached Medicine News:Health News:Houston School Wins National got milk?(R) Refuel Your School Contest 2Health News:Houston School Wins National got milk?(R) Refuel Your School Contest 3Health News:CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS 2Health News:CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS 3Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:Assessing the quality of phase I clinical trial abstracts 2Health News:Assessing the quality of phase I clinical trial abstracts 3Health News:The Hidden Crisis: Commercial Sexual Exploitation of Girls 2Health News:The Hidden Crisis: Commercial Sexual Exploitation of Girls 3Health News:Interventions to Promote Breast-Feeding Succeed 2
Ultrasonic Pachymeter UP-1000 is fast, accurate corneal thickness measurements....
... pachymeter, with compact LCD screen and optional ... portable, weighing slightly more than 2 lbs ... large liquid crystal display. The combination of ... fast precise algorithm enables measurement immediately upon ...
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
Medicine Products: